Daniel Paul Bednarik, PhD

Dr. Bednarík, Chief Technology Officer at Black Canyon Bio, is a seasoned executive scientist and translational entrepreneur with extensive molecular engineering, protein design, and bioinformatics expertise. Dr. Bednarik has over 30 years of experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Sr. Vice President of Molecular Engineering and Protein Design at Neximmune, and VP at Unit at Intrexon Corp., where he led teams of scientists developing innovative methods for cellular therapies for cancer. Prior to that, Dr. Bednarik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednarik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at the Johns Hopkins University Oncology Center.